Retraction: Cip2a Promotes The Survival Of Renal Clear Cell Carcinoma Caki-2 Cells (Retraction Of 10.1002/2211-5463.12870, 2020)

The pathogenesis and progression mechanisms behind renal cancer have always been the focus of urological research, and CIP2A has been identified as an oncoprotein in renal clear cell carcinoma and has been found to play an important role in the invasion and metastasis of cancer cells. Here, we verified the effect of CIP2A on the biological function of renal clear cell carcinoma Caki-2 cells. CIP2A expression was found to be significantly higher in renal clear cell carcinoma tissues than in paracancerous normal tissues (P < 0.001). The cell survival rate in the CIP2A inhibitor group showed a gradual decline from 24 to 72 h, and the difference was statistically significant at different times in the three groups (P < 0.001). The cell survival rate in the NC (negative control) group also showed a gradual decline from 24 to 72 h, and the survival rate in the blank group was significantly lower at 72 and 48 h than at 24 h (P < 0.05). At 48 and 72 h, the cell viability of the CIP2A inhibitor group was significantly lower than that of the NC and blank groups (P < 0.001). The CIP2A inhibitor group exhibited significantly lower numbers of invasive cells and invading cells than the blank group and NC group (P < 0.001). The apoptosis rate in the CIP2A inhibitor group was significantly higher than that in the NC and blank groups (P < 0.05). These finding suggests that CIP2A promotes survival of renal clear cell carcinoma Caki-2 cells.